Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side effects of its obesity and diabetes drugs.

Shares of Eli Lilly plunged after the drug maker reported less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster. The pill helped people ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.

Shares of Eli Lilly & Co. suffered their biggest selloff in 26 years on Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations.

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

Eli Lilly stock crashes as late-stage data for weight-loss pill falls short of expectations. Analyst explains why data wasn't ...